Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sarepta Therapeutics (SRPT)

Sarepta Therapeutics (SRPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,233,011
  • Shares Outstanding, K 104,787
  • Annual Sales, $ 1,902 M
  • Annual Income, $ 235,240 K
  • EBIT $ -124 M
  • EBITDA $ -127 M
  • 60-Month Beta 0.48
  • Price/Sales 0.98
  • Price/Cash Flow 9.36
  • Price/Book 1.69

Options Overview Details

View History
  • Implied Volatility 76.81% (-5.16%)
  • Historical Volatility 59.60%
  • IV Percentile 31%
  • IV Rank 27.61%
  • IV High 193.83% on 07/24/25
  • IV Low 32.18% on 01/22/25
  • Expected Move (DTE 7) 1.43 (6.74%)
  • Put/Call Vol Ratio 1.00
  • Today's Volume 3,009
  • Volume Avg (30-Day) 4,410
  • Put/Call OI Ratio 0.84
  • Today's Open Interest 181,225
  • Open Int (30-Day) 170,618
  • Expected Range 19.75 to 22.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.09
  • Number of Estimates 6
  • High Estimate -0.04
  • Low Estimate -2.10
  • Prior Year 1.50
  • Growth Rate Est. (year over year) -172.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.14 +6.38%
on 12/18/25
24.12 -11.17%
on 01/08/26
-0.89 (-3.97%)
since 12/16/25
3-Month
15.08 +42.08%
on 11/04/25
24.55 -12.73%
on 11/03/25
-1.92 (-8.20%)
since 10/16/25
52-Week
10.41 +105.71%
on 07/24/25
120.05 -82.15%
on 02/05/25
-95.63 (-81.70%)
since 01/16/25

Most Recent Stories

More News
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues

Preliminary total net product revenue of $369.6 million for the fourth quarter and $1.86 billion for full-year 2025 Preliminary...

SRPT : 21.11 (-0.94%)
Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington’s Disease

– The first-in-human clinical study of SRP-1005, known as INSIGHTT, is expected to begin in the second quarter of 2026

SRPT : 21.11 (-0.94%)
Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference...

SRPT : 21.11 (-0.94%)
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Dec. 31, 2025 that were previously approved by the Compensation Committee...

SRPT : 21.11 (-0.94%)
Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has entered into separate, privately negotiated exchange agreements with a...

SRPT : 21.11 (-0.94%)
Is Biogen Stock Outperforming the Dow?

Biogen has notably outpaced the Dow in recent months and over the past year, and analysts remain moderately bullish on the stock’s prospects.

SRPT : 21.11 (-0.94%)
$DOWI : 49,421.20 (-0.04%)
BIIB : 164.30 (-2.53%)
Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Approximately 25 non-ambulatory participants will receive sirolimus as part of the regimen in Cohort 8 of the ENDEAVOR study, which is expected to begin before the end of the year ...

SRPT : 21.11 (-0.94%)
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $200 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT). The milestone was earned when Arrowhead achieved...

ARWR : 64.82 (-2.16%)
SRPT : 21.11 (-0.94%)
Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared progress in the Phase 1/2 multiple ascending dose (MAD) clinical study of SRP-1003 (formerly...

SRPT : 21.11 (-0.94%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are...

SRPT : 21.11 (-0.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. It concentrates on the development of exon-skipping drug candidates targeting Duchenne muscular dystrophy (DMD), a...

See More

Key Turning Points

3rd Resistance Point 24.03
2nd Resistance Point 23.36
1st Resistance Point 22.34
Last Price 21.11
1st Support Level 20.65
2nd Support Level 19.98
3rd Support Level 18.96

See More

52-Week High 120.05
Fibonacci 61.8% 78.17
Fibonacci 50% 65.23
Fibonacci 38.2% 52.30
Last Price 21.11
52-Week Low 10.41

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar